JUPITER NEUROSCIENCES INC (JUNS) Fundamental Analysis & Valuation

NASDAQ:JUNS • US48208B2034

0.37 USD
-0.03 (-7.5%)
At close: Mar 12, 2026
0.39 USD
+0.02 (+5.41%)
After Hours: 3/12/2026, 7:03:17 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This JUNS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

Taking everything into account, JUNS scores 1 out of 10 in our fundamental rating. JUNS was compared to 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of JUNS have multiple concerns. JUNS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. JUNS Profitability Analysis

1.1 Basic Checks

  • JUNS had negative earnings in the past year.
  • JUNS had a negative operating cash flow in the past year.
  • JUNS had negative earnings in each of the past 5 years.
  • In the past 5 years JUNS always reported negative operating cash flow.
JUNS Yearly Net Income VS EBIT VS OCF VS FCFJUNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -1M -2M -3M -4M

1.2 Ratios

  • The Return On Assets of JUNS (-148.62%) is worse than 82.90% of its industry peers.
  • JUNS has a Return On Equity of -440.08%. This is in the lower half of the industry: JUNS underperforms 78.24% of its industry peers.
Industry RankSector Rank
ROA -148.62%
ROE -440.08%
ROIC N/A
ROA(3y)-1786.7%
ROA(5y)-1258.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JUNS Yearly ROA, ROE, ROICJUNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for JUNS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JUNS Yearly Profit, Operating, Gross MarginsJUNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. JUNS Health Analysis

2.1 Basic Checks

  • JUNS has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for JUNS has been increased compared to 5 years ago.
  • JUNS has a better debt/assets ratio than last year.
JUNS Yearly Shares OutstandingJUNS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
JUNS Yearly Total Debt VS Total AssetsJUNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

  • JUNS has an Altman-Z score of -12.10. This is a bad value and indicates that JUNS is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of JUNS (-12.10) is worse than 75.65% of its industry peers.
  • JUNS has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
  • JUNS's Debt to Equity ratio of 0.11 is in line compared to the rest of the industry. JUNS outperforms 50.26% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -12.1
ROIC/WACCN/A
WACCN/A
JUNS Yearly LT Debt VS Equity VS FCFJUNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M -6M

2.3 Liquidity

  • JUNS has a Current Ratio of 1.07. This is a normal value and indicates that JUNS is financially healthy and should not expect problems in meeting its short term obligations.
  • JUNS has a worse Current ratio (1.07) than 80.83% of its industry peers.
  • JUNS has a Quick Ratio of 1.07. This is a normal value and indicates that JUNS is financially healthy and should not expect problems in meeting its short term obligations.
  • JUNS has a Quick ratio of 1.07. This is in the lower half of the industry: JUNS underperforms 76.17% of its industry peers.
Industry RankSector Rank
Current Ratio 1.07
Quick Ratio 1.07
JUNS Yearly Current Assets VS Current LiabilitesJUNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. JUNS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 46.67% over the past year.
EPS 1Y (TTM)46.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-800%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, JUNS will show a very negative growth in Earnings Per Share. The EPS will decrease by -73.25% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-420%
EPS Next 2Y78.89%
EPS Next 3Y-73.25%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
JUNS Yearly Revenue VS EstimatesJUNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2025 2026 2027 2M 4M 6M 8M 10M
JUNS Yearly EPS VS EstimatesJUNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 0 -0.1 -0.2

More info and screens

Find the best growth stocksShow best growing peers

2

4. JUNS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for JUNS. In the last year negative earnings were reported.
  • With a Price/Forward Earnings ratio of 6.05, the valuation of JUNS can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, JUNS is valued cheaper than 93.78% of the companies in the same industry.
  • JUNS's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.82.
Industry RankSector Rank
PE N/A
Fwd PE 6.05
JUNS Price Earnings VS Forward Price EarningsJUNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JUNS Per share dataJUNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 -0.1 -0.15

4.3 Compensation for Growth

  • A cheap valuation may be justified as JUNS's earnings are expected to decrease with -73.25% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y78.89%
EPS Next 3Y-73.25%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. JUNS Dividend Analysis

5.1 Amount

  • JUNS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

JUNS Fundamentals: All Metrics, Ratios and Statistics

JUPITER NEUROSCIENCES INC

NASDAQ:JUNS (3/12/2026, 7:03:17 PM)

After market: 0.39 +0.02 (+5.41%)

0.37

-0.03 (-7.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14
Earnings (Next)N/A
Inst Owners4.67%
Inst Owner Change-53.01%
Ins Owners45.96%
Ins Owner Change0%
Market Cap12.74M
Revenue(TTM)N/A
Net Income(TTM)-5.90M
Analysts82.86
Price Target25.5 (6791.89%)
Short Float %1.51%
Short Ratio0.72
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-30.72%
Min EPS beat(2)-63.4%
Max EPS beat(2)1.96%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 6.05
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 9.51
P/tB 9.51
EV/EBITDA N/A
EPS(TTM)-0.18
EYN/A
EPS(NY)0.06
Fwd EY16.54%
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -148.62%
ROE -440.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1786.7%
ROA(5y)-1258.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.07
Quick Ratio 1.07
Altman-Z -12.1
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-800%
EPS Next Y-420%
EPS Next 2Y78.89%
EPS Next 3Y-73.25%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-714.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-714.93%
OCF growth 3YN/A
OCF growth 5YN/A

JUPITER NEUROSCIENCES INC / JUNS FAQ

What is the ChartMill fundamental rating of JUPITER NEUROSCIENCES INC (JUNS) stock?

ChartMill assigns a fundamental rating of 1 / 10 to JUNS.


Can you provide the valuation status for JUPITER NEUROSCIENCES INC?

ChartMill assigns a valuation rating of 2 / 10 to JUPITER NEUROSCIENCES INC (JUNS). This can be considered as Overvalued.


How profitable is JUPITER NEUROSCIENCES INC (JUNS) stock?

JUPITER NEUROSCIENCES INC (JUNS) has a profitability rating of 0 / 10.


What is the earnings growth outlook for JUPITER NEUROSCIENCES INC?

The Earnings per Share (EPS) of JUPITER NEUROSCIENCES INC (JUNS) is expected to decline by -420% in the next year.